Lilly sells Zepbound vials from $299/mo: compare 11 direct-pay programs →
WeighedHealth
Affiliate disclosure: we earn commission from some partners. Learn more.

Foundayo coupons & savings

orforglipron · manufacturer programs, telehealth bundles, discount cards

Reviewed by the WeighedHealth Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of July 2026; updated when guidance or availability changes.
Jump to section

Orforglipron (brand name Foundayo) is Eli Lilly's once-daily oral GLP-1 receptor agonist, FDA-approved on April 1, 2026 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It is not approved for type 2 diabetes. Self-pay through LillyDirect costs $149-$299/month depending on dose, and the pill can be taken any time of day without food or water restrictions.

Your options

  • RecommendedManufacturer

    LillyDirect Self-Pay

    $149-$299/month by dose

    Eligibility: Valid Foundayo prescription; no insurance required. 0.8 mg and 2.5 mg $149, 5.5 mg $199, 9 mg, 14.5 mg and 17.2 mg $299. The 2.5 mg and 5.5 mg prices are temporary reductions through December 31, 2026; 14.5 mg and 17.2 mg keep the $299 price only when refilled within 45 days.

    Visit LillyDirect →
  • Manufacturer

    Foundayo Savings Card

    as low as $25/month

    Eligibility: Commercial insurance that covers Foundayo. Savings capped at $100 per 1-month fill; program ends December 31, 2026. Government beneficiaries excluded. Coverage varies by plan and may require prior authorization.

    Check Savings Card →

Important notes

  • Newly approved (April 2026) — long-term insurance coverage patterns still developing.
  • Medicare Part D enrollees may qualify for the Medicare GLP-1 Bridge, which covers Foundayo for $50/month from July 1, 2026 through December 31, 2027.
  • Daily oral dosing (vs weekly injection); patients with needle aversion or adherence challenges may benefit from this profile.
  • In ATTAIN-1 the highest dose (17.2 mg) produced 11.2% mean weight loss at 72 weeks vs 2.1% with placebo. Pivotal trials of the injectables reported 14.9% for semaglutide 2.4 mg (STEP 1, 68 weeks) and 20.9% for tirzepatide 15 mg (SURMOUNT-1, 72 weeks); these are separate trials, not head-to-head.

Charity and manufacturer assistance: what is actually open

Status read on each program’s own site on September 16, 2026

3 of the 10 programs below were closed to new applicants on that date, including every charity fund that pays toward a weight-loss GLP-1. We have no relationship with any of them and cannot influence an application. Fund status changes without notice, so confirm on the program’s own page before you count on it.

  • Closed

    TotalAssist (Patient Advocate Foundation; merged with PAN Foundation)

    Obesity fund

    The catch: This is the one charity fund built for weight-loss drugs, and it is closed. Its own rules also require health insurance that already covers the expense, so a cash-pay patient would not qualify even when it is open.

    Income limit as stated
    Have an income at or less than 300% of the Federal Poverty Level, adjusted for your regional Cost of Living Index (COLI)
    Insurance requirement
    Have health insurance that covers your qualifying expenses (fund list row: “Health insurance (any)”)
    Award
    $1,000 guaranteed award | $2,000 maximum award
    Phone
    866-512-3861 (Mon–Fri 8:30am–5:30pm ET)

    Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source

  • Closed

    TotalAssist (Patient Advocate Foundation; merged with PAN Foundation)

    Type 2 diabetes (T2DM) fund

    The catch: Closed, and it was never open to everyone: this fund requires government-insured coverage, so commercially insured and uninsured patients are ineligible. The companion type 2 diabetes health equity fund is closed as well.

    Income limit as stated
    Have an income at or less than 500% of the Federal Poverty Level, adjusted for your regional Cost of Living Index (COLI)
    Insurance requirement
    Have government-insured coverage that covers your qualifying expenses (fund list row: “Government-insured coverage (Medicare, Medicaid, or TRICARE)”)
    Award
    $1,500 guaranteed award | $2,000 maximum award
    Phone
    866-512-3861 (Mon–Fri 8:30am–5:30pm ET)

    Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source

  • Open

    TotalAssist (program-level rules)

    Program-wide eligibility (nearly 150 funds)

    The catch: The program runs, but you can only apply to a fund that is open, and both funds that reach GLP-1s — obesity and type 2 diabetes — were closed on the date checked. A closed fund offers a notification sign-up, not a waitlist queue.

    Income limit as stated
    Have a household income of 500% or less than the Federal Poverty Level (FPL) guidelines, adjusted by the Cost-of-Living Index (COLI) for where the patient lives — with the exception: “Household income of 300% or less than the Federal Poverty Level (only our obesity fund)”
    Insurance requirement
    Have active insurance coverage that includes coverage for pharmaceutical products; the required insurance type varies by fund
    Award
    Varies by fund; grants run on an “individual 12-month rolling grant cycle”
    Phone
    866-512-3861

    Status checked: Open on September 16, 2026. Source

  • Closed

    HealthWell Foundation

    Type 2 Diabetes fund

    The catch: HealthWell has no obesity or weight-management fund at all, so a weight-loss prescription has no route here. The type 2 diabetes fund is the only one that reaches a GLP-1, and it is closed: “This fund is temporarily closed to new patients due to lack of sufficient funding.”

    Income limit as stated
    300–500% of the Federal Poverty Level (fund page); program-wide, “up to 400 or 500 percent of the Federal Poverty Level (somewhat more in cities where the cost of living is higher)”
    Insurance requirement
    “some form of health insurance (private insurance, Medicare, Medicaid, TriCare, etc.) that covers part of the cost of your treatment”; “Drug discount cards do not qualify as insurance.”
    Award
    $1,000 per patient, grant period 12 months
    Phone
    (800) 675-8416 (Mon–Fri 9am–5pm ET)

    Status checked: Closed to new applicants when we checked the program's own page on September 16, 2026. Source

  • Open

    Novo Nordisk Patient Assistance Program (PAP)

    Manufacturer patient assistance program (free medicine)

    The catch: Ozempic is the only GLP-1 on the product list. Wegovy and Saxenda are not on it, so there is no free-medicine route to a branded obesity GLP-1 from Novo Nordisk. For Ozempic the program takes uninsured patients only, at or below 200% of the federal poverty level.

    Income limit as stated
    Ozempic (uninsured): “Total household income must be at or below 200% of the federal poverty level”; insulins and all other products: “Total household income must be at or below 400% of the federal poverty level”
    Insurance requirement
    Must have Medicare or no insurance; private or commercial insurance makes a patient ineligible. For Ozempic, uninsured patients only — Medicare Part D patients are no longer eligible for Ozempic through PAP.
    Award
    Medicine at no cost; approval lasts 12 months for uninsured patients, through the end of the calendar year for Medicare patients
    Phone
    1-866-310-7549 (Mon–Fri 8am–8pm ET)

    Status checked: Open on September 16, 2026. Source

  • Open

    Lilly Cares Foundation

    Lilly Cares Patient Assistance Program

    The catch: The only GLP-1 offered is Trulicity, a type 2 diabetes drug. Zepbound and Mounjaro appear in no medication group and on no Available Medications page, so tirzepatide has no free-medicine route here. Private commercial insurance disqualifies.

    Income limit as stated
    Group 1 Medications (at or below 300% FPL); Group 2 Medications (at or below 400% FPL); Group 3 & Group 4 Medications (at or below 500% FPL) — 2026 FPL guidelines. Household of 1/2/3/4 for Group 1: $47,880 / $64,920 / $81,960 / $99,000.
    Insurance requirement
    For Group 1, 2 and 3 medications, which includes Trulicity: “1) You have no insurance, or 2) you have Medicare Part D (not applicable to infused medications), or 3) you have Medicare Part B but have no supplemental or secondary insurance”
    Award
    Free medication; enrollment generally lasts 12 months or to the end of the enrollment period
    Phone
    1-800-545-6962

    Status checked: Open on September 16, 2026. Source

  • Open

    Patient Advocate Foundation

    Case Management Services & MedCareLine; Financial Aid Funds

    The catch: Case management is advocacy, not money: it does not pay for medication. It is worth a call for an insurance denial or appeal. The grant arm is TotalAssist, whose obesity and type 2 diabetes funds are closed.

    Income limit as stated
    No income threshold is published for case management; TotalAssist income limits apply to grants
    Insurance requirement
    No insurance requirement is stated for advocacy; case management is offered to patients “facing a chronic, life-threatening or debilitating diagnosis”
    Award
    Case management carries no grant; TotalAssist grants vary by fund
    Phone
    Case Management (800) 532-5274 (Mon–Fri 8:30am–5pm ET); TotalAssist (866) 512-3861; Financial Aid Funds (855) 824-7941

    Status checked: Open on September 16, 2026. Source

  • Directory only

    NeedyMeds

    Information directory and free drug discount card

    The catch: NeedyMeds awards no money. It lists other people's programs and issues a discount card — and a discount card is not insurance, which matters because HealthWell states “Drug discount cards do not qualify as insurance.” for its own eligibility.

    Income limit as stated
    None for the discount card: “Can be used by anyone — no financial, age, or residency restrictions”
    Insurance requirement
    None; the card is usable with or without insurance
    Award
    No grant. The card is advertised as “Save up to 80%” on prescriptions.
    Phone
    800-503-6897 (toll-free helpline)

    Status checked: Directory only on September 16, 2026. Source

  • Directory only

    RxAssist

    Directory of patient assistance programs

    The catch: A lookup tool, not a funder: no money, no grants, no application, and no patient helpline published on the site. Use it to find manufacturer programs, not to pay for a prescription.

    Income limit as stated
    None — RxAssist awards nothing; income rules belong to the programs it lists
    Insurance requirement
    None stated
    Award
    No award; directory only
    Phone
    No patient helpline published on the site

    Status checked: Directory only on September 16, 2026. Source

  • Open

    AZ&Me Prescription Savings Program (AstraZeneca)

    Manufacturer patient assistance program

    The catch: No GLP-1 for obesity is offered by this program, and its two diabetes drugs stopped taking new patients: “Effective May 1, 2026, the AZ&Me program will no longer accept new patients for FARXIGA and XIGDUO XR”. Any commercial insurance disqualifies.

    Income limit as stated
    Annual adjusted gross income must be at or below 300% of the Federal Poverty Level (FPL) for Primary and Specialty Medications; 500% of FPL for Rare Disease Medications
    Insurance requirement
    “Not have any commercial (private or employer-sponsored) insurance or government insurance other than Medicare”
    Award
    Medication at no cost, up to a 90-day supply per fill
    Phone
    1-800-292-6363 (Mon–Fri 9:00am–6:00pm ET)

    Status checked: Open on September 16, 2026. Source

Manufacturer copay cards. The Zepbound, Mounjaro, Wegovy and Ozempic savings cards all exclude patients in a government program. The Wegovy terms put it plainly: “Patient is not eligible if he/she is enrolled in any federal or state health care program with prescription drug coverage, such as Medicaid, Medicare, VA, DOD, TRICARE, or any similar federal or state health care program”. If you are on Medicare or Medicaid, the $25 card price is not available to you, whatever the ad says.

Compounded GLP-1s. No program reviewed covers compounded semaglutide or tirzepatide. TotalAssist limits approved medications to products that are “FDA-approved, listed in official compendia, and/or listed in published evidence-based or clinical guidelines”. Manufacturer programs supply only their own branded products.

Telehealth prescriptions. No program reviewed publishes a telehealth exclusion on its own site. Where a prescription was written is not something these programs ask about in their published rules.

More on Foundayo

Frequently asked

What's the cheapest way to get Foundayo?+

Based on the programs currently tracked, the lowest sticker price for Foundayo is "Foundayo Savings Card" at as low as $25/month. Eligibility varies by program — check the requirements for each option above before counting on a price.

Does insurance cover Foundayo?+

Insurance coverage for Foundayo depends on the plan and indication. Many commercial plans cover orforglipron for FDA-approved uses with prior authorization; off-label use is rarely covered. Check your formulary or run your plan through our insurance coverage tool.

Are coupons for Foundayo legitimate?+

Manufacturer programs from Foundayo's maker and federally registered patient assistance foundations are legitimate. Be cautious with discount cards that promise prices far below retail without verifying the dispensing pharmacy is licensed in your state.

What's the best option for Foundayo right now?+

Editorial pick: LillyDirect Self-Pay at $149-$299/month by dose. Valid Foundayo prescription; no insurance required. 0.8 mg and 2.5 mg $149, 5.5 mg $199, 9 mg, 14.5 mg and 17.2 mg $299. The 2.5 mg and 5.5 mg prices are temporary reductions through December 31, 2026; 14.5 mg and 17.2 mg keep the $299 price only when refilled within 45 days. This is a starting point; your situation may favor a different program based on insurance and clinical eligibility.

Share: